Compared with the control regimen , add-on nepafenac resulted in statistically significant reductions in the following parameters : change in macular volume at 3 weeks and 6 weeks ( P < .001 ) , proportion of patients with more than 10 m of swelling in the central macula at 3 weeks ( P < .0001 ) and 6 weeks ( P = .02 ) , mean laser flare intensity at 1 day ( P = .029 ) , pain during the first 24 hours postoperatively ( P < .0001 ) , and ocular discomfort and photophobia during the first 3 postoperative weeks ( P = .0058 and P = .0052 , respectively ) .